• Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

    المصدر: Nasdaq GlobeNewswire / 09 يونيو 2022 07:30:00   America/New_York

    PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Simona King, chief financial officer of Passage Bio, will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference being held from June 13-16, 2022 in Rancho Palos Verdes, CA.

    Format: Fireside Chat
    Date: Thursday, June 16, 2022
    Time: 8:40 a.m. PT (11:40 a.m. ET)

    A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the events.

    About Passage Bio
    Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

    For further information, please contact:

    Investors:
    Stuart Henderson
    Passage Bio
    267.866.0114
    shenderson@passagebio.com

    Media:
    Mike Beyer
    Sam Brown Inc. Healthcare Communications
    312.961.2502
    MikeBeyer@sambrown.com 


    Primary Logo

شارك على،